Nature Communications (Feb 2019)
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Abstract
Cancer cells respond differently to inhibitors of Poly (ADP-ribose) polymerase. Here the authors reveal that ovarian cancer cells with higher cellular NADP+ levels are more sensitive to clinically relevant PARP1 inhibitors and show that NADP+ act as an endogenous inhibitor of PARP enzymes.